HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
benzoyl-prolyl-phenylalanyl-boroarginine
a peptide derivative of arginine boronic acid
Also Known As:
Bz-Pro-Phe-boroArg; P 8720; P-8720; P8720
Networked:
4
relevant articles (
1
outcomes,
0
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Inorganic Chemicals: 9
Boron Compounds: 91
benzoyl-prolyl-phenylalanyl-boroarginine: 4
Organic Chemicals: 133
Boron Compounds: 91
benzoyl-prolyl-phenylalanyl-boroarginine: 4
Amino Acids, Peptides, and Proteins: 1
Peptides: 82426
Oligopeptides: 519
benzoyl-prolyl-phenylalanyl-boroarginine: 4
Experts
1.
Colman, Robert W
: 1 article (11/2005)
2.
Isordia-Salas, Irma
: 1 article (11/2005)
3.
Martínez-Murillo, Carlos
: 1 article (11/2005)
4.
Pixley, Robin A
: 1 article (11/2005)
5.
Sainz, Irma M
: 1 article (11/2005)
Related Diseases
1.
Inflammation (Inflammations)
03/01/1998 - "
Using the selective plasma kallikrein inhibitor P8720, we investigate whether activation of the K-K system plays a primary role in chronic granulomatous intestinal and systemic inflammation in this model.
"
05/01/1996 - "
P8720 therapy significantly but modestly decreased acute intestinal inflammation measured by gross gut score (P < 0.01) and more dramatically reduced the tissue myeloperoxidase activity (P < 0.05), a measure of granulocyte recruitment, in group II compared with group III. We conclude that the K-K system is directly involved in the pathogenesis of the acute phase of experimental acute inflammation.
"
11/01/2005 - "
It has been demostrated that therapy with a specific plasma kallikrein inhibitor (P8720) modulated the experimental enterocolitis, arthritis and systemic inflammation.
"
03/01/1995 - "
We investigate whether the previously shown contact system activation plays a pathogenetic role in a rat model of acute inflammation induced by peptidoglycan-polysaccharide (PG-APS) using a new specific plasma kallikrein inhibitor, Bz-Pro-Phe-boroArg-OH (P8720).
"
03/01/1998 - "
P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P<0.03), and factor XI (P<0.04) in group II vs. group III. P8720 decreased chronic intestinal inflammation measured by blinded gross (P<0.01) and histologic (P<0.0005) scores as well as systemic complications (arthritis, splenomegaly, hepatomegaly, leukocytosis, and acute-phase reaction) (P<0.01) in group II as compared with group III. We conclude that relapsing chronic enterocolitis and systemic complications are in part due to plasma K-K system activation, and that inhibition of this pathway is a potential therapeutic approach to human inflammatory bowel disease and associated extraintestinal manifestations.
"
2.
Arthritis (Polyarthritis)
03/01/1995 - "
Anemia was evident at 49 h in group III but was not present (P < 0.01) in groups I and II. Spleen weight was significantly decreased in group II compared to group III. Acute arthritis progressively developed in group III from 27 to 49 h, but P8720 decreased the joint swelling in group II by 61% (P < 0.0005).
"
11/01/2005 - "
It has been demostrated that therapy with a specific plasma kallikrein inhibitor (P8720) modulated the experimental enterocolitis, arthritis and systemic inflammation.
"
03/01/1998 - "
P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P<0.03), and factor XI (P<0.04) in group II vs. group III. P8720 decreased chronic intestinal inflammation measured by blinded gross (P<0.01) and histologic (P<0.0005) scores as well as systemic complications (arthritis, splenomegaly, hepatomegaly, leukocytosis, and acute-phase reaction) (P<0.01) in group II as compared with group III. We conclude that relapsing chronic enterocolitis and systemic complications are in part due to plasma K-K system activation, and that inhibition of this pathway is a potential therapeutic approach to human inflammatory bowel disease and associated extraintestinal manifestations.
"
3.
Enterocolitis
11/01/2005 - "
It has been demostrated that therapy with a specific plasma kallikrein inhibitor (P8720) modulated the experimental enterocolitis, arthritis and systemic inflammation.
"
03/01/1998 - "
P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P<0.03), and factor XI (P<0.04) in group II vs. group III. P8720 decreased chronic intestinal inflammation measured by blinded gross (P<0.01) and histologic (P<0.0005) scores as well as systemic complications (arthritis, splenomegaly, hepatomegaly, leukocytosis, and acute-phase reaction) (P<0.01) in group II as compared with group III. We conclude that relapsing chronic enterocolitis and systemic complications are in part due to plasma K-K system activation, and that inhibition of this pathway is a potential therapeutic approach to human inflammatory bowel disease and associated extraintestinal manifestations.
"
4.
Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
03/01/1998 - "
P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P<0.03), and factor XI (P<0.04) in group II vs. group III. P8720 decreased chronic intestinal inflammation measured by blinded gross (P<0.01) and histologic (P<0.0005) scores as well as systemic complications (arthritis, splenomegaly, hepatomegaly, leukocytosis, and acute-phase reaction) (P<0.01) in group II as compared with group III. We conclude that relapsing chronic enterocolitis and systemic complications are in part due to plasma K-K system activation, and that inhibition of this pathway is a potential therapeutic approach to human inflammatory bowel disease and associated extraintestinal manifestations.
"
5.
Splenomegaly
03/01/1998 - "
P8720 attenuated the consumption of the contact proteins, high molecular weight kininogen (P<0.03), and factor XI (P<0.04) in group II vs. group III. P8720 decreased chronic intestinal inflammation measured by blinded gross (P<0.01) and histologic (P<0.0005) scores as well as systemic complications (arthritis, splenomegaly, hepatomegaly, leukocytosis, and acute-phase reaction) (P<0.01) in group II as compared with group III. We conclude that relapsing chronic enterocolitis and systemic complications are in part due to plasma K-K system activation, and that inhibition of this pathway is a potential therapeutic approach to human inflammatory bowel disease and associated extraintestinal manifestations.
"
Related Drugs and Biologics
1.
Peroxidase (Myeloperoxidase)
2.
Plasma Kallikrein
3.
benzoyl-prolyl-phenylalanyl-boroarginine
4.
Polysaccharides (Glycans)
5.
Peptidoglycan (Murein)
6.
High-Molecular-Weight Kininogen (Kininogen, High Molecular Weight)
7.
Proteins (Proteins, Gene)
8.
Kinins
9.
Kallikreins (Kallikrein)
10.
Factor XI (Plasma Thromboplastin Antecedent)
Related Therapies and Procedures
1.
Therapeutics